Entrada Therapeutics (TRDA) Stock Forecast, Price Target & Predictions
TRDA Stock Forecast
Entrada Therapeutics stock forecast is as follows: an average price target of $20.00 (represents a 50.83% upside from TRDA’s last price of $13.26) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
TRDA Price Target
The average price target for Entrada Therapeutics (TRDA) is $20.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $20.00. This represents a potential 50.83% upside from TRDA's last price of $13.26.
TRDA Analyst Ratings
According to 3 Wall Street analysts, Entrada Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TRDA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Entrada Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 06, 2024 | Boobalan Pachaiyappan | H.C. Wainwright | $20.00 | $18.02 | 10.96% | 50.83% |
| Jun 25, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $14.24 | 26.40% | 35.75% |
The latest Entrada Therapeutics stock forecast, released on Nov 06, 2024 by Boobalan Pachaiyappan from H.C. Wainwright, set a price target of $20.00, which represents a 10.96% increase from the stock price at the time of the forecast ($18.02), and a 50.83% increase from TRDA last price ($13.26).
Entrada Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $20.00 | $19.00 |
| Last Closing Price | $13.26 | $13.26 | $13.26 |
| Upside/Downside | -100.00% | 50.83% | 43.29% |
In the current month, the average price target of Entrada Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Entrada Therapeutics's last price of $13.26. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Nov 22, 2023 | William Blair | Outperform | Outperform | Hold |
Entrada Therapeutics's last stock rating was published by Cowen & Co. on Aug 14, 2024. The company gave TRDA a "Buy" rating, the same as its previous rate.
Entrada Therapeutics Financial Forecast
Entrada Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $41.85M | $43.73M | - | $25.26M |
| Avg Forecast | $14.11M | $7.05M | $14.11M | $14.11M | $8.78M | $12.32M | $12.32M | $12.32M | $13.12M | $12.32M | $51.86M | $14.98M | $23.69M | $9.60M | $9.78M | $7.00M |
| High Forecast | $16.65M | $8.33M | $16.65M | $16.65M | $10.37M | $14.54M | $14.54M | $13.54M | $15.84M | $14.55M | $61.23M | $14.98M | $31.08M | $9.60M | $11.54M | $8.26M |
| Low Forecast | $10.79M | $5.40M | $10.79M | $10.79M | $6.72M | $9.43M | $9.43M | $9.87M | $11.52M | $9.43M | $39.68M | $14.98M | $12.01M | $9.60M | $7.48M | $5.36M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.77% | 4.56% | - | 3.61% |
Entrada Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $14.98M, with a low forecast of $14.98M, and a high forecast of $14.98M. TRDA's average Quarter revenue forecast represents a -64.21% decrease compared to the company's last Quarter revenue of $41.85M (Dec 23).
Entrada Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.64M | $14.01M | - | $-5.78M |
| Avg Forecast | $11.28M | $5.64M | $11.28M | $11.28M | $7.02M | $9.85M | $9.85M | $9.85M | $10.49M | $9.85M | $41.46M | $11.97M | $18.94M | $7.67M | $7.82M | $5.60M |
| High Forecast | $13.31M | $6.66M | $13.31M | $13.31M | $8.29M | $11.63M | $11.63M | $10.82M | $12.66M | $11.63M | $48.95M | $11.97M | $24.85M | $7.67M | $9.23M | $6.61M |
| Low Forecast | $8.63M | $4.31M | $8.63M | $8.63M | $5.37M | $7.54M | $7.54M | $7.89M | $9.21M | $7.54M | $31.73M | $11.97M | $9.61M | $7.67M | $5.98M | $4.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.30% | 1.83% | - | -1.03% |
2 analysts predict TRDA's average Quarter EBITDA for Mar 24 to be $11.97M, with a high of $11.97M and a low of $11.97M. This is 112.27% upper than Entrada Therapeutics's previous annual EBITDA (Dec 23) of $5.64M.
Entrada Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-9.54M | $35.46M | - | $-6.67M |
| Avg Forecast | $-34.00M | $-38.10M | $-30.11M | $-29.11M | $-36.34M | $-31.34M | $-30.51M | $-29.65M | $-27.25M | $-29.58M | $14.68M | $-24.13M | $-6.84M | $-29.86M | $-28.03M | $-26.46M |
| High Forecast | $-23.62M | $-26.47M | $-20.92M | $-20.22M | $-25.25M | $-21.78M | $-21.20M | $-25.03M | $-25.60M | $-20.55M | $14.69M | $-16.77M | $20.53M | $-20.75M | $-19.47M | $-18.38M |
| Low Forecast | $-41.99M | $-47.05M | $-37.18M | $-35.94M | $-44.87M | $-38.70M | $-37.67M | $-33.12M | $-28.49M | $-36.52M | $14.67M | $-29.80M | $-51.81M | $-36.87M | $-34.61M | $-32.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.39% | -1.19% | - | 0.25% |
Entrada Therapeutics's average Quarter net income forecast for Dec 23 is $-6.84M, with a range of $-51.81M to $20.53M. TRDA's average Quarter net income forecast represents a -119.30% decrease compared to the company's last Quarter net income of $35.46M (Sep 23).
Entrada Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.65M | $7.53M | - | $7.94M |
| Avg Forecast | $11.99M | $6.00M | $11.99M | $11.99M | $7.46M | $10.47M | $10.47M | $10.47M | $11.15M | $10.47M | $44.08M | $12.73M | $20.14M | $8.16M | $8.31M | $5.95M |
| High Forecast | $14.16M | $7.08M | $14.16M | $14.16M | $8.81M | $12.36M | $12.36M | $11.51M | $13.46M | $12.37M | $52.04M | $12.73M | $26.42M | $8.16M | $9.81M | $7.02M |
| Low Forecast | $9.18M | $4.59M | $9.18M | $9.18M | $5.71M | $8.01M | $8.01M | $8.39M | $9.79M | $8.01M | $33.73M | $12.73M | $10.21M | $8.16M | $6.36M | $4.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.92% | - | 1.33% |
Entrada Therapeutics's average Quarter SG&A projection for Mar 24 is $12.73M, based on 2 Wall Street analysts, with a range of $12.73M to $12.73M. The forecast indicates a 47.15% rise compared to TRDA last annual SG&A of $8.65M (Dec 23).
Entrada Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.29 | $1.07 | - | $-0.21 |
| Avg Forecast | $-0.84 | $-0.94 | $-0.74 | $-0.72 | $-0.89 | $-0.77 | $-0.75 | $-0.73 | $-0.67 | $-0.73 | $0.36 | $-0.59 | $-0.17 | $-0.73 | $-0.69 | $-0.65 |
| High Forecast | $-0.58 | $-0.65 | $-0.51 | $-0.50 | $-0.62 | $-0.54 | $-0.52 | $-0.62 | $-0.63 | $-0.51 | $0.36 | $-0.41 | $0.51 | $-0.51 | $-0.48 | $-0.45 |
| Low Forecast | $-1.03 | $-1.16 | $-0.92 | $-0.88 | $-1.10 | $-0.95 | $-0.93 | $-0.82 | $-0.70 | $-0.90 | $0.36 | $-0.73 | $-1.28 | $-0.91 | $-0.85 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.72% | -1.46% | - | 0.32% |
According to 4 Wall Street analysts, Entrada Therapeutics's projected average Quarter EPS for Dec 23 is $-0.17, with a low estimate of $-1.28 and a high estimate of $0.51. This represents a -115.74% decrease compared to TRDA previous annual EPS of $1.07 (Sep 23).
Entrada Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PEPG | PepGen | $1.84 | $29.50 | 1503.26% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| VIGL | Vigil Neuroscience | $2.19 | $11.00 | 402.28% | Buy |
| LRMR | Larimar Therapeutics | $3.71 | $17.00 | 358.22% | Buy |
| PMVP | PMV Pharmaceuticals | $1.43 | $6.00 | 319.58% | Buy |
| THRD | Third Harmonic Bio | $5.20 | $20.00 | 284.62% | Buy |
| CGEM | Cullinan Oncology | $11.25 | $34.00 | 202.22% | Buy |
| OPT | Opthea | $5.07 | $14.00 | 176.13% | Buy |
| PHVS | Pharvaris | $17.64 | $42.00 | 138.10% | Buy |
| TYRA | Tyra Biosciences | $14.65 | $31.75 | 116.72% | Buy |
| CRNX | Crinetics Pharmaceuticals | $39.38 | $69.00 | 75.22% | Buy |
| EWTX | Edgewise Therapeutics | $28.42 | $46.25 | 62.74% | Buy |
| TRDA | Entrada Therapeutics | $13.26 | $20.00 | 50.83% | Buy |
| IRON | Disc Medicine | $55.88 | $77.67 | 38.99% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.96 | $23.25 | 37.09% | Buy |